Foghorn Therapeutics
Yahoo Finance • 28 days ago
IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies
RESEARCH TRIANGLE PARK, N.C. and CAMBRIDGE, Mass., Aug. 28, 2025 /PRNewswire/ -- IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, and Flagship Pioneering, the biop... Full story
Yahoo Finance • 29 days ago
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- August 27, 2025 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnorm... Full story
Yahoo Finance • 5 months ago
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
Company to share new preclinical combination datafor FHD-909 (LY4050784), a potential first-in-class selective SMARCA2 inhibitor, with non-small cell lung cancer (NSCLC) as the primary target population Additional updates include new prec... Full story
Yahoo Finance • 6 months ago
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
- FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Oral presentation on preclinical data for FHD-909 in combination wit... Full story
Yahoo Finance • 7 months ago
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population FHD-909 preclinic... Full story
Yahoo Finance • 7 months ago
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression,... Full story
Yahoo Finance • 2 years ago
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
First patient dosed in FHD-286 combination study in AML; data expected in the second half of 2024Transitioned the BRM Selective inhibitor program to Loxo@Lilly Presented preclinical data demonstrating tumor growth inhibition and favorable... Full story
Yahoo Finance • 2 years ago
Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs
CAMBRIDGE, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression,... Full story
Yahoo Finance • 2 years ago
Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress
CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression,... Full story
Yahoo Finance • 2 years ago
Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference
Pre-clinical data for selective EP300 supports opportunity in solid and hematologic tumor types FHD-286, a potent, selective inhibitor of BRG1 and BRM, shows potential as a broad-based differentiation agent in both clinical and pre-clinica... Full story
Yahoo Finance • 2 years ago
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression... Full story
Yahoo Finance • 2 years ago
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma
- Clinical data support safety and tolerability profile of FHD-286, a highly potent, - selective, allosteric, oral, small molecule inhibitor of BRG1/BRM - Clinical activity observed in late-line metastatic uveal melanoma includes nine pa... Full story
Yahoo Finance • 2 years ago
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry
The company's MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules precisely tuned for therapeutic benefit With $50 million in committed capital from Flagship, Metaphore has built a first-in... Full story
Yahoo Finance • 2 years ago
Foghorn Therapeutics Provides an Update on FHD-609
CAMBRIDGE, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression... Full story
Yahoo Finance • 2 years ago
Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression... Full story
Yahoo Finance • 2 years ago
Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting
Foghorn Therapeutics, Inc. CAMBRIDGE, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correctin... Full story
Yahoo Finance • 3 years ago
Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update
- Phase 1 dose escalation study of FHD-286, a BRG1/BRM inhibitor, in metastatic uveal melanoma continues to progress with initial safety and efficacy data expected in the first half of 2023 - Phase 1 dose escalation study of FHD-609, a se... Full story
Yahoo Finance • 3 years ago
Foghorn Therapeutics to Participate at Cowen’s 43rd Annual Health Care Conference
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression... Full story
Yahoo Finance • 3 years ago
Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs
Logica, an offering from Charles River and Valo Health will be deployed by Pioneering Medicines across a portfolio of targets WILMINGTON, Mass. & CAMBRIDGE, Mass., February 16, 2023--(BUSINESS WIRE)--Charles River Laboratories Internation... Full story
Yahoo Finance • 3 years ago
Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023
- Phase 1 dose escalation study of FHD-286, a BRG1/BRM inhibitor, in metastatic uveal melanoma continues to progress with initial efficacy and safety data expected in the first half of 2023 - Phase 1 dose escalation study of FHD-609, a se... Full story
